Investors citing Dexcom stock forecast 2025 highlight expanding pediatric CGM adoption, a segment with high lifetime customer value and recurring revenue potential. Dexcom occupies around 74% of the CGM market share in the US, according to analysis by GlobalData. It is known for its continuous glucose monitors (CGMs) – gaining particular spotlight when it received FDA-approval for the first over-the-counter CGM in March 2024. The company also made headlines when it partnered with ŌURA , pumping $75m into the smart-ring developer’s Series D financing round to integrate their respective technologies. This configuration is modestly more bullish than three months ago, with 16 analysts suggesting a “Strong Buy” rating. The Dexcom stock forecast 2025 benefits from strategic alliances with digital health platforms, integrating CGM data into broader chronic disease management ecosystems.